Pfizer (PFE): DoD awarded $23K
DoD awarded Pfizer a contract with $23K committed so far.
- $23K
- committed so far
- Signed
- Apr 23, 2026
- Updated
- Apr 23, 2026
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Nov 26, 2024CongressDisclosed sale of PFE — reported range $1,001 - $15,000
- Mar 10, 2025CongressDisclosed sale of PFE — reported range $15,001 - $50,000
- Feb 10, 2026CongressDisclosed purchase of PFE — reported range $1,001 - $15,000
- Feb 24, 2026FDAFDA drug approval: Braftovi
- Feb 24, 2026FDAFDA drug approval: Braftovi
- Feb 26, 2026Government · Federal Register noticeDetermination of Regulatory Review Period for Purposes of Patent Extension; ORLYNVAH
- Mar 6, 2026FDAFDA drug approval: Xeljanz
- Mar 6, 2026FDAFDA drug approval: Xeljanz XR
- Mar 9, 2026Government · Federal Register noticeAspen Global Inc. c/o Lachman Consultant Services, Inc., et al.; Withdrawal of Approval of 46 New Drug Applications
- Mar 13, 2026CongressDisclosed partial sale of PFE — reported range $1,001 - $15,000
- Mar 24, 2026CongressDisclosed sale of PFE — reported range $50,001 - $100,000
- Mar 27, 20265% stakeThe Vanguard Group reported a passive stake (13G)
- Apr 3, 2026Government · Federal Register noticeDetermination of Regulatory Review Period for Purposes of Patent Extension; HYMPAVZI
- Apr 8, 2026Federal contract · $15K obligatedDepartment of Defense awarded Pfizer: $15K obligated to date
- Apr 23, 2026 · this disclosureFederal contract · $23K obligatedDepartment of Defense awarded Pfizer: $23K obligated to date
What came next
- Apr 23, 2026Federal contract · $2K obligatedDepartment of Defense awarded Pfizer: $2.2K obligated to date
- May 1, 20265% stakeVanguard Capital Management reported a passive stake (13G) of 7.5%
- May 5, 2026Company filing · Form 8-K · ResultsReported its results
- May 13, 2026Federal contract · $25K obligatedDepartment of Defense awarded Pfizer: $25K obligated to date
- May 15, 2026Federal contract · $543K obligatedDepartment of Health and Human Services awarded Pfizer: $543K obligated to date
- May 20, 2026Federal contract · $2K obligatedDepartment of Defense awarded Pfizer: $2.2K obligated to date
- Jun 5, 2026FDAFDA drug approval: Hympavzi
- Jun 8, 2026Government · Federal Register noticeDetermination That Protamine Sulfate (Protamine Sulfate) Intravenous; Solution, 50 Milligrams/5 Milliliters, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- Jun 8, 2026CongressDisclosed sale of PFE — reported range $15,001 - $50,000
- Jun 9, 2026InsiderOfficer sold ~$51K of PFE shares in the open market
- Jun 18, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On June 16, 2026, Dave Denton notified Pfizer Inc. (the “Company”) that he will step down from his current position as Chief Financial Officer effective August 15, 2026 for a professional opportunity outside of the pharmaceutical industry in consumer goods, and that his departure is not related to the Company’s financial or operating results or to any disagreements with the Company regarding the Company’s financial,…”
- Jun 24, 2026FDAFDA drug approval: Ibrance
- Jun 24, 2026FDAFDA drug approval: Ibrance
- Jul 6, 2026Government · Federal Register noticeEndo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
- Jul 15, 2026Federal contract · $5K obligatedDepartment of Defense awarded Pfizer: $4.9K obligated to date
- Jul 20, 2026Government · Federal Register noticeForeign-Trade Zone (FTZ) 43, Notification of Proposed Production Activity; Pfizer Inc.; (Pharmaceutical Products); Kalamazoo and Portage, Michigan
- Aug 4, 2026Company filing · Form 8-K · ResultsReported its results
- Aug 5, 2026Insider · 3 peopleInsiders: 2 purchases (~$2.0M), 1 sale (~$83K)
- Aug 12, 2026Insider · Their first buy on recordCEO purchased ~$1M of PFE shares in the open market
- Aug 21, 2026Government · Federal Register noticeAdvisory Committee; Oncologic Drugs Advisory Committee; Renewal
How to read USAspending.gov award record
The obligated amount is money the government has legally committed to pay and has set aside in its accounts. The ceiling, which USAspending calls the potential value, is the most the contract could be worth if every option is exercised and every possible order is placed. The ceiling is a limit, not a payment, and it is often many times the obligated amount.
Full guide: Contract ceiling vs obligated amount: the difference
What else is on file for Pfizer
For Pfizer, OQRO holds 1 fund holdings report (13F) and 1 federal contract award dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its PFE page.
How this filing works
Explore the data
Common questions
What federal contract did Pfizer (PFE) receive?
DoD awarded Pfizer a contract with $23K committed so far. Defense Logistics Agency.
When did it happen, and when was it made public?
Signed: Apr 23, 2026. Updated: Apr 23, 2026.
Is the contract value money the company has received?
No. The award record gives the amount committed so far and a ceiling the contract may reach. Neither is revenue: the company is paid as the work is delivered, and a contract can be cut short.
Where does this information come from?
From the USAspending.gov award record, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about Pfizer recently?
For Pfizer, OQRO holds 1 fund holdings report (13F) and 1 federal contract award dated in the last 90 days. They are listed on the PFE page.
Does this mean PFE stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Pfizer
- SEC Form 13F-HRNov 16, 2026
- USAspending.gov award recordNov 12, 2026
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRAug 14, 2026
Everything OQRO holds on this company is on its PFE page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
